Announcement PDF ASX ANNOUNCEMENT 9 September 2026 New Activated Probiotics launches for H1 FY27 ●​ Biome will launch two new products in H1 FY27: Biome Daily Probiotic 60 and Biome Daily Kids Probiotic 60, two-month formats of the Company’s two highest volume products ●​ Both are clinically supported daily probiotics for gastrointestinal symptoms, the side effects of antibiotics and winter immune support, microencapsulated so five times more live bacteria reach the gut²,³ ●​ Biome Daily (30) is the number one probiotic product in Australian pharmacy by both units and value, and Biome Daily Kids (30) is the number one immune health and kids probiotic, based on IQVIA pharmacy scan data¹ ●​ 14 of the top 20 probiotic products in Australian pharmacy are 60 or 90 packs (IQVIA). Biome Daily and Biome Daily Kids reached number one in 30 packs alone, and the Company's modelling indicates new sales are expected to run well ahead of any substitution from the 30 packs ●​ Supplied through the Company's existing pharmacy wholesalers and practitioner channel from H1 FY27, spreading demand across more SKUs and de-risking supply of the Company's largest lines ●​ The new products will be Biome's first Australian-made products, manufactured under its onshore manufacturing agreement with Specialty Probiotics Australia (refer ASX announcement 3 June 2026) Microbiome health company Biome Australia Limited (ASX: BIO) (‘Biome’ or ‘the Company’) is pleased to announce two new products for launch in H1 FY27: Biome Daily Probiotic 60 and Biome Daily Kids Probiotic 60, two-month formats of the two highest volume products in its Activated Probiotics range. ​ Clinically Studied Probiotic Medicines Biome Daily Probiotic is a six strain, 9 billion live bacteria capsule for adults, formulated for digestive and immune health. Its HEAL9 and 8700:2 strain combination has been studied in randomised, double-blind, placebo-controlled trials in more than 1,400 adults and shown to reduce the incidence, duration and severity of common colds.² Biome Daily Kids Probiotic is a five strain, 10 billion live bacteria vanilla flavoured sachet for children from two years, formulated to support immune function, reduce the occurrence and duration of common colds and maintain healthy gut bacteria during antibiotic use, and includes Lactobacillus rhamnosus GG, one of the most studied strains in children. Both use Activated Probiotics’ microencapsulation technology, which protects the bacteria through the stomach so that five times more reach the gut alive than uncoated probiotics.³ Biome Daily sits in digestive probiotics, the largest segment of the pharmacy probiotic category, and Biome Daily Kids leads the immunity segment.¹ Building on two number one products Independent IQVIA pharmacy scan data ranks Biome Daily as the number one probiotic product in Australian pharmacy by both units and value, and Biome Daily Kids as the number one immune health and kids probiotic.¹ Both reached those positions with a 30 pack alone, against brands whose core lines are 60 and 90 packs. The same data shows 14 of the top 20 probiotic products by value are 60 or 90 packs, and three of the six 30 packs in the top 20 are Biome’s own.¹ The new products bring the Company’s two category leaders into the format that leads the category. Commercial rationale Probiotics work through consistent daily use. A two-month supply supports adherence and retention, gives pharmacists and practitioners a simpler recommendation for regular users, and lifts transaction value for pharmacy partners. Pricing has been set to retain existing customers as they move to the larger format. Both new products will be supplied through the Company’s existing community pharmacy wholesalers and the practitioner channel during the first half of FY27. They also de-risk the Company’s two largest lines. Demand that currently sits on a single SKU for each product will be spread across two, reducing the impact of any out of stock at wholesaler or retailer level. The format is structurally more efficient for Biome, with one carton, one label and one freight movement covering two months of supply, which supports the Company’s stated objective of lifting gross margin as manufacturing moves onshore under its agreement with Specialty Probiotics Australia (refer ASX announcement 3 June 2026). The Company has modelled the interaction between the formats across a range of scenarios. In each, growth in new sales is expected to run well ahead of any substitution from the 30 packs. No revenue guidance is provided for the new products. Managing Director commentary Biome Australia Founder and Managing Director, Blair Vega Norfolk, said: “Our probiotics are backed by clinical trials, but a trial result only becomes a health outcome if people take the product every day for long enough to get the benefit. The most common reason they stop is running out. A two-month pack helps patients stay on the product, and gives the pharmacists and practitioners who support them a simpler recommendation. The data shows how much room there is to grow. Biome Daily and Biome Daily Kids became the number one probiotics in Australian pharmacy in a 30 pack, against brands whose core lines are 60s and 90s. Fourteen of the top twenty products in the category are larger formats. Until now we have left that part to everyone else. That’s why this may be the most exciting launch we’ve done. Patients stay on the product longer, practitioners get an easier recommendation, and the category has already told us it wants the format. These will also be Biome’s first Australian-made products.” ¹ IQVIA Pharmacy Scan, Australian community pharmacy, pack level, MAT 52 weeks to 4 July 2026, national, category VMS15 Probiotics. Biome Daily: number one probiotic product by units and value. Biome Daily Kids: number one product in the immunity probiotics segment and number one children’s probiotic product by value and units. Top 20 ranked by MAT sales value. Digestive probiotics segment share of category value. ² Berggren A et al. Eur J Nutr 2011;50(3):203-210 (n=272); Busch R et al. Food Nutr Sci 2013;4:13-20 (n=310); Lazou Ahrén I et al. J Nutr 2021;151(1):214-222 (n=898). Randomised, double-blind, placebo-controlled trials of L. plantarum HEAL9 and L. paracasei 8700:2 in adults, 12 weeks, 1 billion CFU daily. ³ Del Piano M et al. J Clin Gastroenterol 2010;44(Suppl 1):S42-46. Gastro-protected microencapsulated strains delivered comparable intestinal colonisation at one fifth of the dose of the same strains uncoated. -ENDS- Approved for release by the Biome Australia board of directors. For further information Investor Relations: Lauren Dwyer, CFO, corporate@biomeaustralia.com Media enquiries: media@activated.co About Biome Australia Limited Biome Australia develops, licenses, commercialises and markets innovative, evidence-based live biotherapeutics and complementary medicines with clinically proven health benefits. Incorporated in Australia in 2018, Biome distributes locally and internationally. In partnership with leading microbiome research organisations, Biome produces unique live biotherapeutic products with innovative delivery technologies improving stability and efficacy for its flagship Activated Probiotics range. Supported by randomised double-blind placebo-controlled clinical trials, Activated Probiotics and Activated Therapeutics help prevent and support management of various health concerns including low mood and sleep, bone health, iron malabsorption, mild eczema and IBS. Through practitioner-recommended distribution, Biome educates health professionals on gut microbiota’s systemic health effects, providing evidence-based natural medicines for prevalent chronic health concerns. For more information visit www.biomeaustralia.com Forward looking statements This release may contain forward looking statements, including but not limited to projections, guidance on future revenues, earnings and estimates, and the future performance of Biome (Forward Looking Statements). Forward Looking Statements are provided as general guidance only and should not be relied upon as an indication or guarantee of future performance. The Forward Looking Statements are based on information available to Biome as at the date of this release. Nothing in this release is a promise or representation as to the future. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any Forward Looking Statements contained in this release. Except as required by law or regulation (including the ASX Listing Rules), Biome does not undertake to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise. To the maximum extent permitted by law, Biome excludes and expressly disclaims all liabilities in respect of, and makes no representation or warranty, express or implied as to the fairness, currency, accuracy, reliability or completeness of information in this release or the accuracy, likelihood of achievement or reasonableness of any Forward Looking Statements contained in, or implied by, the information in this release or any part of it, or that this release contains all material information about Biome or which a prospective investor or purchaser may require in evaluating a possible investment in Biome or acquisition of securities in Biome.